Veracyte Capital Expenditures Over Time

VCYT Stock  USD 41.18  0.19  0.46%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Veracyte Performance and Veracyte Correlation.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
  
Capital Expenditures is likely to gain to about 10.5 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.13)
Revenue Per Share
5.644
Quarterly Revenue Growth
0.286
Return On Assets
0.0107
Return On Equity
(0.01)
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capital Expenditures Analysis

Compare Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Capital Expenditures Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CRNX190 K190 K190 K190 K190 K190 K190 K304 K1.1 M492 K186 K436 K1.7 M4.7 M4.9 M
CYTK6.6 M443 K125 K542 K1.1 M562 K1.6 M2.9 M889 K2.6 M11.1 M48.9 M11.3 M1.4 M1.3 M
GPCR19.019.019.019.019.019.019.019.019.019.019.01.2 K155 K2.2 M2.3 M
KURA0.00.00.00.084.064 K0.02.2 M2.2 M2.2 M2.2 M1.1 M626 K168 K159.6 K
PTGX299 K299 K299 K299 K299 K399 K379 K666 K486 K967 K471 K1.1 M795 K609 K678.9 K
MRUS114.6 K114.6 K114.6 K114.6 K190.9 K112.6 K521.6 K868.6 K4.2 M2.6 M1.3 M870 K7.6 MM2.2 M
REPL238 K238 K238 K238 K238 K238 K238 K136 K2.6 M6.5 M2.4 M2.3 M2.3 M5.7 MM
ENTA37 K252 K606 KM2.3 M4.7 M2.5 MM5.4 M1.4 M750 K2.1 M9.1 M17.9 M18.8 M
SNDX11 K11 K11 K38 KK49 K261 K84 K187 K129 K129 K129 K225 K0.00.0
VTYX262 K262 K262 K262 K262 K262 K262 K262 K262 K262 K262 K262 K275 K514 K346.5 K
QURE400.5 K400.5 K1.2 M8.3 M23.3 M9.4 M17.2 M5.6 M4.2 M6.6 M9.5 M17.4 M17.7 M7.2 M10.8 M
RCKT0.00.00.00.0412 K412 K487 K70 K1.5 M23.3 M29.1 M7.7 M8.6 M16.5 M17.3 M
RYTM0.00.00.00.017 K17 K1.1 M133 K722 K3.4 M214 K5.4 M4.3 M47 K44.6 K
SLDB392 K392 K392 K392 K392 K392 K392 K2.3 M7.8 M4.4 M899 K1.3 MM1.5 M2.7 M
MGTX2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M10.5 M11.3 MM37 M55.2 M45 M20.2 M26.2 M
IDYA1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.7 M1.4 M493 K2.6 M3.4 M2.4 M2.2 M
ANAB37 K37 K37 K37 K145 K238 K50 K290 K1.1 M805 K569 K1.4 M358 K807 K572.8 K
KROS217 K217 K217 K217 K217 K217 K217 K217 K217 K271 K294 KM1.2 M2.5 M2.6 M

Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Capital Expenditures description

Capital Expenditures are funds used by Veracyte to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Veracyte operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

My Equities

My Current Equities and Potential Positions

Veracyte
VCYT
ClassificationHealthcare
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 41.18

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.